


CERTIFICATE UNDER 37 CFR § 1.10 OF MAILING BY "EXPRESS MAIL"
I hereby certify that this correspondence is being deposited with the United States Postal Services "Express Mail Post Office to Addressee" service under 37 CFR § 1.10 on the date indicated above and is addressed to Mail Stop AF, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Name: Sarah Barnett

Express Mail Label No.: EV 533070728 US

Signature: *Sarah Barnett*

Date: September 2, 2004



PATENT

Customer No. 22,852

Attorney Docket No. 09367.0018-06000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of)
FINER, Jeffrey T. et al.) Examiner: Tamthom Ngo TRUONG
Application No. 09/724,778) Group Art Unit: 1624
Filed: November 28, 2000) Confirmation No. 9331
For: METHODS AND COMPOSITIONS)
UTILIZING QUINAZOLINONES)

Commissioner of Patents
P.O. Box 1450
Alexandria, VA 22313-1450
Mail Stop AF

Sir:

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(d)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(d), Applicants bring to the attention of the Examiner the documents listed on the attached Form PTO 1449. This Information Disclosure Statement is being filed after a Final Action and is accompanied by a fee of \$180.00 as specified under § 1.17(p). Applicants respectfully request that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form.

Copies of the listed documents, including any copending patent applications, are attached. English translations of the abstracts of the four non-English documents are enclosed.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or

constitute "prior art." If the Examiner applies any of the documents as prior art against any claims in the application and Applicants determine that the cited documents do not constitute "prior art" under United States law, Applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of such documents.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Date: September 2, 2004

By: 

Lauren L. Stevens

Reg. No. 36,691

Telephone: 650-849-6614

Facsimile: 650-849-6666



OMB No. 0651-0011

INFORMATION DISCLOSURE CITATION

Atty. Docket No.	09300018-06000	Appln. No.	09/724,778
Applicant	FINER, Jeffrey T. et al.		
Filing Date	November 28, 2000	Group:	1624

U.S. PATENT DOCUMENTS

Examiner Initial*		Document Number	Issue/Pub. Date	Name	Class	Sub Class	Filing Date If Appropriate
	1.	2001/0046997 A1	11/29/01	Abraham et al.			
	2.	2002/0032207 A1	03/14/02	Thompson et al.			
	3.	2002/0055519 A1	05/09/02	Thompson et al.			
	4.	2002/0165221 A1	11/07/02	Baxter et al.			
	5.	2003/0018038 A1	01/23/03	Thompson et al.			
	6.	2003/0119834 A1	06/26/03	Bamdad			
	7.	2003/0130293 A1	07/10/03	Bamdad			
	8.	2003/0139398 A1	07/24/03	Hoekstra et al.			
	9.	2003/0144350 A1	07/31/03	Stevenson et al.			
	10.	2003/0158188 A1	08/21/03	Lee et al.			
	11.	2003/0158198 A1	08/21/03	Lee et al.			
	12.	2003/0166933 A1	09/04/03	Bergnes et al.			
	13.	2003/0171387 A1	09/11/03	Sun et al.			
	14.	2003/0195211 A1	10/16/03	Sadhu et al.			
	15.	2003/0220338 A1	11/27/03	Watkins et al.			
	16.	2003/0220356 A1	11/27/03	Ibrahim et al.			
	17.	2004/0067969 A1	04/08/04	Bergnes et al.			
	18.	2004/0077662 A1	04/22/04	Zhou et al.			
	19.	2004/0077667 A1	04/22/04	Matsuoka et al.			
	20.	2004/0092561 A1	05/13/04	Ruckle et al.			
	21.	5,444,061	08/22/95	Bisset et al.			
	22.	5,492,915	02/20/96	Dereu et al.			
	23.	5,892,114	04/06/99	Goldmann et al.			

CERTIFICATE UNDER 37 CFR § 1.10 OF MAILING BY "EXPRESS MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Services "Express Mail Post Office to Addressee" service under 37 CFR § 1.10 on the date indicated above and is addressed to Mail Stop AF, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Name: Sarah Barnett

Express Mail Label No.: EV 533070728 US

Signature:

Date: September 2, 2004



INFORMATION DISCLOSURE CITATION


Atty. Docket No.	09367.0010-06000	Appln. No.	09/724,778
Applicant	FINER, Jeffrey T. et al.		
Filing Date	November 28, 2000	Group:	1624

FOREIGN PATENT DOCUMENTS

		Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No
	24.	AU B-12617/88	09/15/88	Australia			
	25.	WO 01/16114 A2	03/08/01	WIPO			
	26.	WO 01/30768 A1	05/03/01	WIPO			
	27.	WO 01/32171 A1	05/10/01	WIPO			
	28.	WO 01/32634 A1	05/10/01	WIPO			
	29.	WO 01/81346 A2	11/01/01	WIPO			
	30.	WO 02/083143 A1	10/24/02	WIPO			
	31.	WO 02/094790 A1	11/28/02	WIPO			Abstract
	32.	WO 03/063800 A2	08/07/03	WIPO			
	33.	WO 03/076418 A1	09/18/03	WIPO			
	34.	WO 03/097053 A1	11/27/03	WIPO			
	35.	WO 03/103575 A2	12/18/03	WIPO			
	36.	WO 03/106435 A1	12/24/03	WIPO			
	37.	WO 2004/006916 A1	01/22/04	WIPO			
	38.	WO 2004/020599 A2	03/11/04	WIPO			
	39.	WO 2004/022554 A1	03/18/04	WIPO			
	40.	WO 97/10221	03/20/97	WIPO			
	41.	WO 98/26664	06/25/98	WIPO			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	42.	Ahmad et al. "Monoamine oxidase Inhibitory Activity of 4 (3H)-Quinazolinones of Dopamine" <i>Indian J. of Pharm. Sci.</i> 126-127 (1979)
	43.	Chenard et al. "Quinazolin-4-one α -Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid (AMPA) Receptor Antagonists: Structure-Activity Relationship of the C-2 Side Chain Tether" <i>J. Med. Chem</i> 44:1710-1717 (2001)
	44.	El-Sharief et al. "Oxidation of 3-aminoquinazolinones with lead tetraacetate. A novel synthesis of naphtho-fused azirino-pyrazolo- and 1,4,5-oxadiazepino-quinazolinones" <i>J. Chem Research (S)</i> : 205-208 (2002)
	45.	Garg et al. "Synthesis and anti-implantation activity of α -(2-aryl-3-ethyl-4-oxo (3H) quinazolinyl)- α -(substituted styryl)-cyclohexa-none thiosemicarbazones" <i>Biol. Mem.</i> 14(2):180-186 (1988)



INFORMATION DISCLOSURE CITATION

Att'y. Docket No.	09367.0018-06000	Appln. No.	09/724,778
Applicant	FINER, Jeffrey T. et al.		
Filing Date	November 28, 2000	Group:	1624

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

46.	Gyimesi-Forras et al. "Optical Resolution of a Series of Potential Cholecystokinin Antagonist 4(3H)-Quinazolone Derivatives by Chiral Liquid Chromatography on α_1 -Acid Glycoprotein Stationary Phase" <i>J. of Chromat. Sci.</i> 38:430-434 (2000)
47.	Hassanein et al. "Sythesis of 2-substituted-10H-[1,2,4] triazino [6,1-b] quinazoline-10-ones and 8,13,14,16 tetrahydronaphtho [2',3':,3,4] [1,2,5] triazepino [7,1-b] quinazoline-8,13,1 6-triones with biological interest" <i>Al-Azhar Bull. Sci.</i> 8(2):417-434 (1997)
48.	Hughes et al. "Quinazoline Antifolate Thymidylate Synthase Inhibitors: Alkyl, Substituted Alkyl, and Aryl Substituents in the C2 Position" <i>J. Med. Chem.</i> 33:3060-3067 (1990)
49.	Jiang et al. "A Salt Bridge between an N-terminal Coiled Coil of gp41 and an Antiviral Agent Targeted to the gp41 Core Is Important for Anti-HIV-1 Activity" <i>Biochem. and Biophys. Res. Communications</i> 270:153-157 (2000)
50.	Kokosi et al. "Nitrogen Bridgehead Compounds Part 90. An Efficient Versatile Synthesis of 1-Methyl-2-substituted 1,2,3,4-Tetrahydro-6H-Pyrazino[2,1-b]Quinazoline-3,6-Diones" <i>Heterocycles</i> 48(9):1851-1866 (1998)
51.	Krisztina et al. "Az AGP-alapu folyadek-kromatografias allofazis alkalmazasa kinazonon szarmazekok enantiomerjeinek elvalasztasaban" <i>Acta Pharma. Hungarica</i> 73:5-12 (translation of abstract provided) (2003)
52.	Monika et al. "Potencialis CCK-antagonista kinazonon-szarmazekok szintezse" <i>Acta Pharma. Hungarica</i> 133-136 (translation of abstract provided) (1995)
53.	Monika et al. "Uj kinazolonszarmazekok szintezise es ciklizalasa [1,4]oxazepino- es [1,4]diazepino [3,4-b]kinazononkka" <i>Magyar Kemiai Folyoirat</i> 102:343-355 (translation of abstract provided) (1996)
54.	Panday, V.K. "Possible Antiparkinsonian Compounds Part XI: Synthesis of 2-aryl/alkyl-3-[β -(3'-4'-dihydroxyphenyl) ethyl]-quinazolin (3H)-4-one and 2-aryl/alkyl-3-[(7'-(phenothiazinyl)-ethyl)-quinazolin/(3H)-4-one" <i>Acta Ciencia Indica</i> 4(3):230-235 (1978)
55.	Pandey et al. "Quinazolyl-thiazoles as CNS acting agents" <i>Acta Pharm.</i> 46:51-59 (1996)
56.	Pandey, V.K. "Antiparkinsonism and CNS Activities of 2-aryl alkyl-3-{ β -(3'-4'-dihydroxyphenyl) Ethyl}-quinazolin (3H) 4-ones" <i>Biol. Mem.</i> 11(2):213-215 (1985)
57.	Reddy et al. "4-Heteryl- β -lactams: A facile synthesis of 1-aryl-4-[isopropylideneamino/methyl-4(3H)-oxoquinazolin-2-yl] azetidin-2-ones" <i>Indian J. of Chem.</i> 38B:40-44 (1999)
58.	Reddy et al. "A New Synthesis of 2-aryl-2H-Pyrazino[2,1- β]Quinazolin-3,6(1H,4H)-Diones" <i>Synthetic Communications</i> 21(2):173-181 (1991)
59.	Reddy et al. "Bisazaheterocycles: Part VII - Synthesis of novel bisquinazolinonyl β -lactams" <i>Ind. J. of Chem.</i> 41B:1946-1949 (2002)
60.	Reddy et al. "Synthesis of 2-quinazolinonyl imidazolidinones" <i>Ind. J. of Chem.</i> 42B:393-396 (2003)
61.	Singh et al. "Synthesis and pharmacological screening of some 2-aryl-3-(phenyl-aryl-hydrazonyl)-quinazolin (3H) 4-ones" <i>Indian Drugs</i> 28(2):70-74 (1990)



OMB No. 0651-0011

INFORMATION DISCLOSURE CITATION

Atty. Docket No.	09367.0018-00000	Appln. No.	09/724,778
Applicant	FINER, Jeffrey T. et al.		
Filing Date	November 28, 2000	Group:	1624

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
62.	Szabo et al. "Nitrogen Bridgehead Compounds: Part 88 [1], Synthesis of 3H,7H-[1,4]Diazepino[3,4-b]quinazoline-3,7-diones" <i>J. Heterocyclic Chem.</i> 34(21):21-25 (1997)	
63.	Tiwari et al. "Possible Antifertility Compounds Part III: Synthesis of 2-Hippuryl-3-Aryl-Quinazolinones" <i>J. Chem. Soc. Pak.</i> 3(4):215-217 (1981)	

Examiner	Date Considered
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	
Form PTO 1449	Patent and Trademark Office - U.S. Department of Commerce